BRAF and amyotrophic lateral sclerosis: By combining this model of MN toxicity with proteomics and phosphoproteomics, we identified druggable targets capable of protecting ALS MNs from ER stress-associated toxicity, including PKC and BRAF signaling components (Figure 6B).